Ricci M, Del Prete G F, Maggi E, Romagnani S
Respiration. 1986;50 Suppl 2:103-15. doi: 10.1159/000195108.
The central role of IgE antibodies in allergic bronchial asthma (ABA) is not disputed any longer. Immunological mechanisms other than IgE-mediated reactions in the pathogenesis of ABA have not yet been definitely demonstrated. There is controversy as to whether IgG STS antibodies, probably IgG4, play a role in the disease process. There is no evidence to support the involvement of immune complexes. Anti-beta-2-adrenergic receptor autoimmune responses cannot be considered as responsible for the development of the disease at the present time. In the last few years a great effort has been made to understand the immunological mechanisms underlying the enhanced and long-standing IgE antibody production in atopic diseases. The results obtained in different laboratories, including our own, are in favor of a high responder status to allergen epitopes in a large proportion of atopics and suggest that a preferential expression of IgE isotype in the antibody responses may occur through different mechanisms. Of great interest is the recent demonstration of IgE-binding factors with IgE-potentiating and suppressive activity and of other related regulatory molecules and receptors. Progress has been recently achieved in the characterization of mediators responsible for the different pathological changes of ABA. A linkage between immediate IgE-mediated reactions, bronchial late-phase reactions (LPR) and chronic inflammation (CI) has been reported. It has been demonstrated that a cascade of mediators and cell interactions induce both LPR and CI. There is evidence of a close relationship between LPR-CI and nonspecific bronchial hyperreactivity. A better knowledge of pathogenetic mechanisms of ABA would open new perspectives in the therapy. A modulation of IgE antibody production can be attempted in different ways. At present a control of mediator release and of airway hyperreactivity can be achieved by several pharmacological interventions and by the avoidance of common and/or occupational allergens or pollutants.
IgE抗体在过敏性支气管哮喘(ABA)中的核心作用已不再有争议。ABA发病机制中除IgE介导反应之外的免疫机制尚未得到明确证实。关于IgG STS抗体(可能是IgG4)是否在疾病进程中发挥作用存在争议。没有证据支持免疫复合物的参与。目前,抗β-2肾上腺素能受体自身免疫反应不能被认为是导致该疾病发生的原因。在过去几年中,人们付出了巨大努力来了解特应性疾病中IgE抗体产生增强和持续存在的免疫机制。包括我们自己实验室在内的不同实验室所获得的结果表明,大部分特应性个体对过敏原表位具有高反应者状态,并且提示抗体反应中IgE同种型的优先表达可能通过不同机制发生。最近发现具有IgE增强和抑制活性的IgE结合因子以及其他相关调节分子和受体,这一点非常有趣。最近在确定导致ABA不同病理变化的介质方面取得了进展。据报道,即刻IgE介导反应、支气管迟发相反应(LPR)和慢性炎症(CI)之间存在联系。已经证明,一系列介质和细胞相互作用可诱导LPR和CI。有证据表明LPR-CI与非特异性支气管高反应性之间存在密切关系。更好地了解ABA的发病机制将为治疗开辟新的前景。可以尝试通过不同方式调节IgE抗体的产生。目前,通过几种药物干预以及避免常见和/或职业性过敏原或污染物,可以实现对介质释放和气道高反应性的控制。